Related Experiment Videos
[Poseidonol in the treatment of patients with hyperlipidemia]
Insights
Poseidonol demonstrated significant antilipidemic effects, reducing cholesterol and triglycerides while increasing high-density lipoproteins in patients with cardiovascular and liver conditions. No adverse effects were observed, suggesting a favorable safety profile.
Area of Science:
- Cardiovascular Medicine
- Hepatology
- Nephrology
Background:
- Hyperlipidemia is a significant risk factor for ischemic heart disease, chronic liver disease, and kidney conditions.
- Existing treatments for hyperlipidemia may have limitations or adverse effects.
- Poseidonol is a compound being investigated for its potential health benefits.
Purpose of the Study:
- To evaluate the antilipidemic effects of poseidonol in patients with hyperlipidemia.
- To assess the impact of poseidonol on lipid profiles in patients with ischemic heart disease, secondary pyelonephritis, and chronic hepatosis-hepatitis.
- To determine the safety and tolerability of poseidonol in these patient groups.
Main Methods:
- A study involving 123 patients with ischemic heart disease, 40 with secondary pyelonephritis, and 40 with chronic hepatosis-hepatitis, all presenting with hyperlipidemia.
- Administration of poseidonol to all patient groups.
- Monitoring of lipid profiles, including cholesterol, triglycerides, B-lipoproteins, and high-density lipoproteins.
- Assessment of liver and kidney function to evaluate safety.
Main Results:
- Significant reductions in cholesterol levels (25.4%, 20.6%, 18.7%) and triglycerides (63%, 42%, 21.4%) across the studied groups.
- Marked increase in high-density lipoproteins (40.2%, 27%, 69.9%).
- No observed adverse effects on liver or kidney function.
Conclusions:
- Poseidonol exhibits a potent antilipidemic effect, effectively improving lipid profiles in patients with hyperlipidemia.
- The compound demonstrates a favorable safety profile, with no negative impact on liver or kidney function.
- Poseidonol represents a promising therapeutic agent for managing hyperlipidemia and associated cardiovascular and hepatic conditions.
Abstract:
An antilipidemic effect of poseidonol was tested in 123 patients with ischemic heart disease, stable angina of effort (II-III functional class), 40 patients with secondary pyelonephritis and 40 patients with chronic hepatosis-hepatitis associated with chronic alcoholism or diabetes mellitus. The patients had also hyperlipidemia. A positive effect of poseidonol was established: cholesterol content fell by 25.4, 20.6 and 18.7%, respectively; triglycerides level decreased by 63, 42 and 21.4%, respectively; B-lipoproteins fell by 55.5, 36.9 and 13.1%, respectively. High density lipoproteins rose by 40.2, 27 and 69.9%, respectively. No adverse effects either on the liver or kidney functions were observed.